Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
On July 31, 2024, Adial announced that, after an extensive review of data and information from the Onward Study, it had filed a new patent application to protect core assets and extend IP exclusivity ...
Targeted Oncology3d
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...